Liver Transplant Rejection - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 81 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Liver Transplant Rejection - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Liver Transplant Rejection - Pipeline Review, H2 2016', provides an overview of the Liver Transplant Rejection pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Liver Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Liver Transplant Rejection and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Liver Transplant Rejection
- The report reviews pipeline therapeutics for Liver Transplant Rejection by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Liver Transplant Rejection therapeutics and enlists all their major and minor projects
- The report assesses Liver Transplant Rejection therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Liver Transplant Rejection

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Liver Transplant Rejection
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Liver Transplant Rejection pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Liver Transplant Rejection Overview 7
Therapeutics Development 8
Pipeline Products for Liver Transplant Rejection - Overview 8
Pipeline Products for Liver Transplant Rejection - Comparative Analysis 9
Liver Transplant Rejection - Therapeutics under Development by Companies 10
Liver Transplant Rejection - Therapeutics under Investigation by Universities/Institutes 11
Liver Transplant Rejection - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Liver Transplant Rejection - Products under Development by Companies 15
Liver Transplant Rejection - Products under Investigation by Universities/Institutes 16
Liver Transplant Rejection - Companies Involved in Therapeutics Development 17
Astellas Pharma Inc. 17
Biogen Inc 18
Conatus Pharmaceuticals Inc. 19
Digna Biotech, S.L. 20
Dompe Farmaceutici S.p.A. 21
Novartis AG 22
RedHill Biopharma Ltd. 23
Liver Transplant Rejection - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
ABC-294640 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Cardiotrophin-1 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Cellular Immunotherapy for Liver Transplantation - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Cellular Immunotherapy for Liver Transplantation - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
emricasan - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
everolimus - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
FX-06 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
reparixin - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
rituximab - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
tacrolimus ER - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
TR-002 - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
Liver Transplant Rejection - Dormant Projects 71
Liver Transplant Rejection - Discontinued Products 72
Liver Transplant Rejection - Product Development Milestones 73
Featured News & Press Releases 73
Nov 16, 2015: Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting 73
May 12, 2014: Conatus Pharmaceuticals Initiates Phase 2b Trial Targeting Fibrosis in Liver Transplant Recipients 73
Nov 02, 2013: Conatus Pharmaceuticals Presents Data Demonstrating Emricasan's Safety Profile at the AASLD Liver Meeting 74
Dec 04, 2012: Astellas Pharma Announces Acceptance Of US New Drug Application For Tacrolimus Extended Release Capsules 75
Oct 20, 2011: European Medicines Agency Agrees To Precautionary Recall Of Advagraf 0.5mg Capsule Batches 75
Jul 01, 2011: Astellas Introduces Advagraf In India 76
Mar 16, 2011: Digna Biotech And Biotecnol Receive Spanish Approval For Phase I Clinical Studies Of Cardiotrophin I 76
Feb 18, 2011: Astellas Introduces Advagraf in China-once daily administration, leading the new trend in immunosuppressive therapy after organ transplant 76
Oct 02, 2007: New Once-Daily Advagraf Launched Across Europe. 77
Jun 18, 2007: Advagraf Now Available in Germany and the UK as a Once-Daily Immunosuppressant in Organ Transplantation 78
Apr 30, 2007: Advagraf Now Approved Across Europe as a Once-Daily Immunosuppressant in Organ Transplantation. 79
Appendix 80
Methodology 80
Coverage 80
Secondary Research 80
Primary Research 80
Expert Panel Validation 80
Contact Us 80
Disclaimer 81

List of Tables

Number of Products under Development for Liver Transplant Rejection, H2 2016 8
Number of Products under Development for Liver Transplant Rejection - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Development, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Liver Transplant Rejection - Pipeline by Astellas Pharma Inc., H2 2016 17
Liver Transplant Rejection - Pipeline by Biogen Inc, H2 2016 18
Liver Transplant Rejection - Pipeline by Conatus Pharmaceuticals Inc., H2 2016 19
Liver Transplant Rejection - Pipeline by Digna Biotech, S.L., H2 2016 20
Liver Transplant Rejection - Pipeline by Dompe Farmaceutici S.p.A., H2 2016 21
Liver Transplant Rejection - Pipeline by Novartis AG, H2 2016 22
Liver Transplant Rejection - Pipeline by RedHill Biopharma Ltd., H2 2016 23
Assessment by Monotherapy Products, H2 2016 24
Number of Products by Stage and Target, H2 2016 26
Number of Products by Stage and Mechanism of Action, H2 2016 28
Number of Products by Stage and Route of Administration, H2 2016 30
Number of Products by Stage and Molecule Type, H2 2016 32
Liver Transplant Rejection - Dormant Projects, H2 2016 71
Liver Transplant Rejection - Discontinued Products, H2 2016 72